Clinical proteomics firm Somalogic has begun validation of its protein biomarker-based diagnostics for pancreatic cancer and mesothelioma. View full post on mesothelioma – Yahoo! News Search Results
U.S. researchers have discovered specific changes in the blood of patients with two deadly cancers that may allow doctors to diagnose them at an earlier stage. View full post on Yahoo! News Search Results for mesothelioma
Using a novel aptamer-based proteomics array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer — pancreatic … View full post on mesothelioma – Bing News
Using a novel aptamer-based proteomics array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer – pancreatic and mesothelioma. This technology would enable better clinical diagnosis at an earlier stage and may provide insight [...]
U.S. researchers have discovered specific changes in the blood of patients with two deadly cancers that may allow doctors to diagnose them at an earlier stage. Using new screening technology developed by privately held Somalogic Inc, company researchers said o View full post on mesothelioma – Bing News
( Washington University School of Medicine ) Pancreatic tumors can be identified by a readily detectable marker that shows promise as a basis for immune therapy against the disease, according to research at Washington University School of Medicine in St. Louis.
